1. International consensus statement on allergy and rhinology:Allergic rhinitis - 2023
- Author
-
Sarah K. Wise, Cecelia Damask, Lauren T. Roland, Charles Ebert, Joshua M. Levy, Sandra Lin, Amber Luong, Kenneth Rodriguez, Ahmad R. Sedaghat, Elina Toskala, Jennifer Villwock, Baharudin Abdullah, Cezmi Akdis, Jeremiah A. Alt, Ignacio J. Ansotegui, Antoine Azar, Fuad Baroody, Michael S. Benninger, Jonathan Bernstein, Christopher Brook, Raewyn Campbell, Thomas Casale, Mohamad Chaaban, Fook Tim Chew, Jeffrey Chambliss, Antonella Cianferoni, Adnan Custovic, Elizabeth Mahoney Davis, John M. DelGaudio, Anne K. Ellis, Carrie Flanagan, Wytske J. Fokkens, Christine Franzese, Matthew Greenhawt, Amarbir Gill, Ashleigh Halderman, Jens M. Hohlfeld, Cristoforo Incorvaia, Stephanie A. Joe, Shyam Joshi, Merin Elizabeth Kuruvilla, Jean Kim, Adam M. Klein, Helene J. Krouse, Edward C. Kuan, David Lang, Desiree Larenas‐Linnemann, Adrienne M. Laury, Matt Lechner, Stella E. Lee, Victoria S. Lee, Patricia Loftus, Sonya Marcus, Haidy Marzouk, Jose Mattos, Edward McCoul, Erik Melen, James W. Mims, Joaquim Mullol, Jayakar V. Nayak, John Oppenheimer, Richard R. Orlandi, Katie Phillips, Michael Platt, Murugappan Ramanathan, Mallory Raymond, Chae‐Seo Rhee, Sietze Reitsma, Matthew Ryan, Joaquin Sastre, Rodney J. Schlosser, Theodore A. Schuman, Marcus S. Shaker, Aziz Sheikh, Kristine A. Smith, Michael B. Soyka, Masayoshi Takashima, Monica Tang, Pongsakorn Tantilipikorn, Malcolm B. Taw, Jody Tversky, Matthew A. Tyler, Maria C. Veling, Dana Wallace, De Yun Wang, Andrew White, Luo Zhang, Omar G. Ahmed, Khashayar Arianpour, Emily Barrow, Carlo Cavaliere, Juan Carlos Ceballos Cantu, Mark B. Chaskes, Andy Jian Kai Chua, Srihari Daggumati, Luke Daines, Paul Daraei, Thomas Edwards, Deanna Gigliotti, Mitchell Gore, Khodayar Goshtasbi, Doo Hee Han, Lubnaa Hossenbaccus, Megan Jolicoeur, Dichapong Kanjanawasee, Suat Kilic, Sophia Linton, David Liu, Christoper Low, Chengetai Mahomva, Jordan A. Malenke, Amar Miglani, Peter Nagy, Jin‐A Park, Marianella Paz‐Lansberg, Paul Pfeffer, Marisa Ryan, Anirudh Saraswathula, Cameron Sheehan, Nadja Struss, Kevin Tie, Sina Torabi, Esmond F. Tsai, Nathalia Velasquez, Jackson Vuncannon, Duncan Watley, and Xinni Xu
- Subjects
microbiome ,IgE ,allergen extract ,allergen immunotherapy ,allergic rhinitis ,allergy ,antihistamine ,asthma ,atopic dermatitis ,avoidance ,biologic ,cockroach ,conjunctivitis ,consensus ,corticosteroid ,cough ,cromolyn ,decongestant ,environment ,eosinophilic esophagitis ,epicutaneous ,epidemiology ,evidence-based medicine ,food allergy ,house dust mite ,immunoglobulin E ,immunotherapy ,inhalant allergy ,leukotriene ,occupational rhinitis ,omalizumab ,pediatric ,perennial ,pet dander ,pollen ,probiotic ,rhinitis ,rhinosinusitis ,saline ,seasonal ,sensitization ,sinusitis ,socioeconomic ,specific IgE ,subcutaneous immunotherapy ,sublingual immunotherapy ,systematic review ,total IgE ,transcutaneous immunotherapy ,validated survey ,Immunology and Allergy ,Otorhinolaryngology - Abstract
BACKGROUND: In the 5 years that have passed since the publication of the 2018 International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR-Allergic Rhinitis 2018), the literature has expanded substantially. The ICAR-Allergic Rhinitis 2023 update presents 144 individual topics on allergic rhinitis (AR), expanded by over 40 topics from the 2018 document. Originally presented topics from 2018 have also been reviewed and updated. The executive summary highlights key evidence-based findings and recommendation from the full document.METHODS: ICAR-Allergic Rhinitis 2023 employed established evidence-based review with recommendation (EBRR) methodology to individually evaluate each topic. Stepwise iterative peer review and consensus was performed for each topic. The final document was then collated and includes the results of this work.RESULTS: ICAR-Allergic Rhinitis 2023 includes 10 major content areas and 144 individual topics related to AR. For a substantial proportion of topics included, an aggregate grade of evidence is presented, which is determined by collating the levels of evidence for each available study identified in the literature. For topics in which a diagnostic or therapeutic intervention is considered, a recommendation summary is presented, which considers the aggregate grade of evidence, benefit, harm, and cost.CONCLUSION: The ICAR-Allergic Rhinitis 2023 update provides a comprehensive evaluation of AR and the currently available evidence. It is this evidence that contributes to our current knowledge base and recommendations for patient evaluation and treatment.
- Published
- 2023